[ad_1]
A Washington woman has succumbed to a rare coagulation syndrome after receiving the J&J COVID-19 vaccine, marking the first such death confirmed in the state, health officials said.
The woman, whose name has not been released by county or state health officials, was in her 30s and resided in King County. She received the vaccine on August 26, 2021 and died more than a week later on September 7, according to a statement.
JOHNSON & JOHNSON COVID-19 VACCINE-RELATED RARE CLOT RISK SHOULD BE EXPLAINED TO YOUNGER WOMEN, Says CDC
The cause of death was thrombosis with thrombocytopenia syndrome (TTS), according to Seattle & King County Public Health, which described TTS as a rare but serious disease in recipients of the J&J vaccine. The CDC’s clinical vaccination safety assessment project confirmed the diagnosis, officials noted, adding that the CDC had reported three more nationally confirmed deaths from the complication.
“Unfortunately, this is the first such death in Washington state,” Secretary of State for Health Dr. Umair A. Shah said in a statement Tuesday. “We extend our deepest condolences to his family and loved ones. Losing a loved one at any time is a tragic and difficult pain… which has become all too familiar in the past year and a half of this pandemic.”
The state health department said it will work closely with county and federal health officials as more details become available.
In late April, federal health officials lifted an 11-day hiatus on J&J use COVID-19[female[feminine vaccine following a review and recommendation of a panel of experts who determined it complies with safety standards despite rare cases of severe blood clots.
CLICK HERE TO GET THE FOX NEWS APP
“We concluded that the known and potential benefits of the Janssen COVID-19 vaccine outweigh its known and potential risks in people 18 years of age and older,” Acting FDA Commissioner Janet Woodcock said in a previous press release. “We are confident that this vaccine continues to meet our standards for safety, efficacy and quality.”
Information sheets accompanying the J&J COVID-19 vaccine warn of the remote risk of blood clots and low platelet levels, with symptoms usually appearing within two weeks of vaccination. Women aged 18 to 49 are associated with the highest reporting rates. Despite the rare risk, health authorities advise immediate medical attention for the following symptoms after receiving the J&J vaccine, such as shortness of breath, chest pain, leg swelling, persistent abdominal pain, severe or persistent headache, or blurred vision. and bruises or tiny spots of blood under the skin beyond the injection site.
[ad_2]
Source link